Skip to content

ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

 
  • En
  • Sv
  • About us
    • Management
    • Board of Directors
  • Therapeutic areas
    • Liver metastases
    • Gastric Cancer
  • Pipeline
    • Orviglance®
    • Oncoral
  • Partnering
  • Investors
    • Press releases
    • Financial reports
    • Presentations & articles
    • Events
    • Share information
    • Shareholders
    • Insiders
    • Equity research
    • Financial calendar
  • Governance
    • General Meeting
    • Articles of Association
    • Nomination Committee
    • Board of Directors
    • Audit Committee
    • Remuneration Committee
    • Commercialization Committee
    • Remuneration
    • Auditors
    • Internal control
  • Career
    • Open positions
    • Our values
  • Contact
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
Subscribe to press releases
All All press releasesRegulatory press releasesFinancial reports
Regulatory
2025-05-16 | Quarterly Report Q1 2025: Positive Outcome of Orviglance FDA Meeting in Advance of the NDA Submission
PDF
Report
Presentation
Webcast
Regulatory
2025-05-07 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 7 May 2025
PDF
Report
Presentation
Webcast
Regulatory
2025-04-30 | Change in Number of Shares and Votes in Ascelia Pharma AB
PDF
Report
Presentation
Webcast
Regulatory
2025-04-16 | Ascelia Pharma Receives Gross Proceeds of SEK 43 Million from Exercise of Warrants Series TO 1
PDF
Report
Presentation
Webcast
Regulatory
2025-04-11 | Annual Report 2024: Orviglance Advances to Registration Phase after Successful Phase 3 Study Completion
PDF
ESEF
Report
Presentation
Webcast
2025-04-08 | Ascelia Pharma Announces Publication of Orviglance Study in Investigative Radiology
PDF
Report
Presentation
Webcast
Regulatory
2025-04-04 | Notice of Annual General Meeting in Ascelia Pharma AB
PDF
Report
Presentation
Webcast
2025-04-04 | Ascelia Pharma Announces Acceptance of Study on Burden of Illness Real-World Data of Orviglance Target Patients for Presentation at the ISPOR 2025 Conference
PDF
Report
Presentation
Webcast
Regulatory
2025-03-31 | The Subscription Price for Warrants Series TO 1 in Ascelia Pharma has been Determined to SEK 2.15 and the Exercise Period is Initiated on 1 April 2025
PDF
Report
Presentation
Webcast
Regulatory
2025-03-18 | Ascelia Pharma Announces Positive Outcomes of FDA Meeting and Confirms Plan to Submit the NDA for Orviglance mid-2025
PDF
Report
Presentation
Webcast
Regulatory
2025-02-25 | Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 25 February 2025
PDF
Report
Presentation
Webcast
Regulatory
2025-02-12 | Nomination Committee Appointed for AGM 2025 in Ascelia Pharma AB
PDF
Report
Presentation
Webcast
Regulatory
2025-02-07 | Q4 and Full Year Report 2024: Completion of Full Study Report Reinforces Successful Outcomes of SPARKLE Phase 3 Study
PDF
Report
Presentation
Webcast
Regulatory
2025-01-30 | NOTICE OF EXTRAORDINARY GENERAL MEETING IN ASCELIA PHARMA AB
PDF
Report
Presentation
Webcast
2025-01-27 | Ascelia Pharma Announces Acceptance of Three Scientific Abstracts with SPARKLE Phase 3 Data at the European Society of Gastrointestinal and Abdominal Radiology Annual Meeting
PDF
Report
Presentation
Webcast
2024-12-23 | Ascelia Pharma Patent Granted in China for Second Generation Orviglance
PDF
Report
Presentation
Webcast
2024-12-17 | Ascelia Pharma Announces Acceptance of SPARKLE Phase 3 Data for Presentation at the Society of Abdominal Radiology Congress 2025
PDF
Report
Presentation
Webcast
2024-12-02 | Ascelia Pharma Presents Orviglance SPARKLE Study Primary Results as Cutting-Edge Research at the 2024 RSNA Annual Meeting
PDF
Report
Presentation
Webcast

Posts navigation

Older posts
Learn more

About us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. […]
Learn more

Contact

Ascelia Pharma AB (publ) (ticker: ACE) today presents the primary results from the Orviglance® phase 3 SPARKLE Study as an oral presentation at the world’s largest radiology conference, RSNA, in Chicago.As communicated earlier, in the successful SPARKLE study, Orviglance significantly improved the visualization of focal liver lesions comp ...
Learn more

Our values

Our values inspire our ambitions, decision making and collaboration to help us reach our highest potential. INTEGRITY We build powerful relationship with mutual respect and adhere to the high ethical […]
  1. Start (en)

About us

  • Start (en)
  • About us
  • Career
  • Contact
  • Privacy policy
  • About cookies
  • Cookie settings
  • IMPORTANT INFORMATION

Pipeline

  • Oncoral
  • Orviglance®

IR & Media

  • Subscribe to press releases
  • Press releases & News
  • Financial Reports

Contact us

Ascelia Pharma AB
Hyllie Boulevard 34
215 32 Malmö
Sweden
Phone: +46 735 17 91 18

info@ascelia.com

Follow us

 

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (former working name Mangoral) and Oncoral – in clinical development.

Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

© Copyright 2021 - Ascelia Pharma AB | We use cookies to improve our services | Disclaimer Market data could be delayed. Delivered by Modular Finance.

Video
Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all